Sector News

Wren Therapeutics raises £12.4m in latest financing round

January 31, 2021
Life sciences

Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.

The latest financing round was led by the company’s existing shareholder The Baupost Group, with new investors including Schooner Capital and Industry Ventures. Other existing investors, including LifeForce Capital, also participated.

Wren, a spin-off company from both the University of Cambridge in the UK and Lund University in Sweden, is focused on drug discovery and development for the treatment of protein misfolding diseases.

The company has utilised the capital raised so far to advance its lead small molecule programmes, targeting amyloid-beta and alpha-synuclein – with the first clinical candidate for amyloid-β set for Q1 2021.

Last December, Wren also signed a research collaboration agreement with Eisai to discover new small molecules for the potential treatment of synucleinopathies.

Synucleinopathies are neurodegenerative disease characterised by the misfolding and aggregation of a-synuclein in neurons and glial cells.

This includes Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy.

Wren has also expanded its pipeline to included three additional targets – including IAAP for diabetes, tua for Alzheimer’s disease and other tauopathies, and TDP-43 for motor neurone disease.

“The new capital, alongside our recently announced collaboration with Eisai, is a further endorsement of our unique chemical kinetics platform that has been industrialised by the Wren team over the previous four years, building on more than a decade of prior academic research,” said Samuel Cohen, chief executive officer of Wren.

“Our mission is to radically advance drug discovery for a wide range of protein misfolding diseases by creating molecules that will offer transformative therapeutic options for millions of patients globally suffering from these increasingly common medical disorders,” he added.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).